Traws Pharma, Inc. Prepaid Expense and Other Assets, Current
Traws Pharma, Inc. (TRAW) had Prepaid Expense and Other Assets, Current of $553.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes
us-gaap:PrepaidExpenseAndOtherAssetsCurrent · last filed 2026-08-14
- 2026-06-30: Prepaid Expense and Other Assets, Current $553.00K.
- 2026-03-31: Prepaid Expense and Other Assets, Current $845.00K.
- 2025-12-31: Prepaid Expense and Other Assets, Current $365.00K.
- 2025-09-30: Prepaid Expense and Other Assets, Current $1.21M.
| Period end | Prepaid Expense and Other Assets, Current | Prepaid Expense and Other Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $553.00K 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $845.00K 10-Q · filed 2026-05-15 | |
| 2025-12-31 | $365.00K 10-Q · filed 2026-08-14 | |
| 2025-09-30 | $1.21M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $966.00K 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $1.26M 10-Q · filed 2025-05-15 | |
| 2024-12-31 | $1.85M 10-K · filed 2026-04-15 | |
| 2024-09-30 | $1.39M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $1.77M 10-Q · filed 2024-08-15 | |
| 2024-03-31 | $1.75M 10-Q · filed 2024-05-15 | |
| 2023-12-31 | $1.82M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $1.75M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $704.00K 10-Q · filed 2023-08-14 | |
| 2023-03-31 | $802.00K 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $561.00K 10-K · filed 2024-04-01 | |
| 2022-09-30 | $1.11M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $1.47M 10-Q · filed 2022-08-15 | |
| 2022-03-31 | $583.00K 10-Q · filed 2022-05-13 | |
| 2021-12-31 | $332.00K 10-K · filed 2023-03-30 | |
| 2021-09-30 | $529.00K 10-Q · filed 2021-11-15 | |
| 2021-06-30 | $457.00K 10-Q · filed 2021-08-16 | |
| 2021-03-31 | $607.00K 10-Q · filed 2021-05-17 | |
| 2020-12-31 | $722.00K 10-K · filed 2022-03-21 | |
| 2020-09-30 | $757.00K 10-Q · filed 2020-11-16 | |
| 2020-06-30 | $720.00K 10-Q · filed 2020-08-12 | |
| 2020-03-31 | $795.00K 10-Q · filed 2020-05-15 | |
| 2019-12-31 | $650.00K 10-K · filed 2021-03-18 | |
| 2019-09-30 | $957.00K 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $833.00K 10-Q · filed 2019-08-14 | |
| 2019-03-31 | $759.00K 10-Q · filed 2019-05-15 | |
| 2018-12-31 | $760.00K 10-K · filed 2020-03-27 | |
| 2018-09-30 | $696.00K 10-Q · filed 2018-11-14 | |
| 2018-06-30 | $545.00K 10-Q · filed 2018-08-14 | |
| 2018-03-31 | $814.00K 10-Q · filed 2018-05-15 | |
| 2017-12-31 | $820.00K 10-K · filed 2019-04-01 | |
| 2017-09-30 | $1.00M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $711.00K 10-Q · filed 2017-08-14 | |
| 2017-03-31 | $848.00K 10-Q · filed 2017-05-15 | |
| 2016-12-31 | $1.59M 10-K · filed 2018-03-16 | |
| 2016-09-30 | $1.17M 10-Q · filed 2016-11-14 | |
| 2016-06-30 | $975.00K 10-Q · filed 2016-08-15 | |
| 2016-03-31 | $1.15M 10-Q · filed 2016-05-11 | |
| 2015-12-31 | $1.83M 10-K · filed 2017-03-29 | |
| 2015-09-30 | $1.90M 10-Q · filed 2015-11-12 | |
| 2015-06-30 | $2.02M 10-Q · filed 2015-08-13 | |
| 2015-03-31 | $2.60M 10-Q · filed 2015-05-15 | |
| 2014-12-31 | $3.07M 10-K · filed 2016-03-28 | $3.20M 10-K · filed 2015-03-30 |
| 2014-09-30 | $4.28M 10-Q · filed 2014-11-14 | |
| 2014-06-30 | $3.33M 10-Q · filed 2014-08-14 | |
| 2014-03-31 | $4.40M 10-Q · filed 2014-05-15 | |
| 2013-12-31 | $4.39M 10-K · filed 2015-03-30 | |
| 2013-09-30 | $5.33M 10-Q · filed 2013-11-14 | |
| 2013-06-30 | $5.87M 10-Q · filed 2013-09-06 | |
| 2012-12-31 | $1.73M 10-K · filed 2014-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |